Emerging drugs for non-small cell lung cancer

Bibliography

• GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statistics, 2001. CA Cancer J. Clin. (2001) 51:15–36.
   PubMed Web of Science ®Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• •First study demonstrating a statistically significant advantage for platinum-based chemotherapy in advanced NSCLC.
   Google Scholar
• CARDENAL F, LOPEZ-CABRERIZO M, ANTON A et al.: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.' Clin. Oncol. (1999) 17:12–18.
   Web of Science ®Google Scholar
• CRINO L, SCAGLIOTTI GV, RICCI S et al.: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. Clin. Oncol. (1999) 17:3522–3530.
   Web of Science ®Google Scholar
• SANDLER A, NEMUNAITIS J, DEHNAM C et al.: Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Clin. Oncol. (2000) 18:122–130.
   Web of Science ®Google Scholar
• GIACCONE G, SPLINTER TA, DEBRUYNE C et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Clin. Oncol (1998) 6:2133–2141.
   Google Scholar
• WOZNIAK AJ, CROWLEY JJ, BALCERZAK SP et al.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. I Clin. Oncol (1998) 16:2459–2465.
   Web of Science ®Google Scholar
• BONOMI P, KIM K, FAIRCLOUGH D et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. Clin. Oncol (2000) 18:623–631.
   Web of Science ®Google Scholar
• LE CHEVALIER T, BRISGAND D, DOUILLARD JY et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.' Clin. Omni (1994) 12:360–367.
   PubMed Web of Science ®Google Scholar
• DANSON S, CLEMONS M, MIDDLETON M et al.: A randomised study of gemcitabine with carboplatin (GC) versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2001) 20:322a.
   Google Scholar
• SEDERHOLM C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a Phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc. Am. Soc. Clin. Oncol (2002) 21:291a.
   Web of Science ®Google Scholar
• LILENBAUM RC, HERNDON J, LIST M et al.: Single agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (Q0L), and cost-effectiveness. Proc. Am. Soc. Clin. Omni (2002) 21:1a.
   Web of Science ®Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI CP et al: Comparison of four chemotherapy regimens for advanced non- small-cell lung cancer. N Engl. J. Med. (2002) 346:92–98.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating the substantial equivalence of new platinum-based doublets in NSCLC.
   Google Scholar
• SCAGLIOTTI GV, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. " Clin. Oncol (2002) 20:4285–4292.
   Web of Science ®Google Scholar
• VAN MEERBEECK JP, SMIT EF, LIANES P et al: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Omni (2001) 20:308a.
   Google Scholar
• HUANG SM, HARARI PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs (1999) 17:259–269.
   PubMed Web of Science ®Google Scholar
• ROBERT F, EZEKIEL MP, SPENCER SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.j Clin. Oncol (2001) 19:3234–3243.
   Web of Science ®Google Scholar
• KIM ES, MAUER AM, FOSSELLA FV et al.: A Phase II study of erbitux (imc-c225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/ resistant patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Omni (2002) 21:293a.
   Google Scholar
• PAULETTI G, DANDEKAR S, RONG H et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. Clin. Omni (2000) 18:3651–3664.
   PubMed Web of Science ®Google Scholar
• PAULETTI G, GOD OLPHIN W, PRESS MF, SLAMON DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene (1996) 13:63–72.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A, MCGUIRE WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177–182.
   PubMed Web of Science ®Google Scholar
• RAVDIN PM, CHAMNESS GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene (1995) 159:19–27.
   PubMed Web of Science ®Google Scholar
• SESHADRI R, FIRGAIRA FA, HORSFALL DJ, MCCAUL K, SETLUR V, KITCHEN P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Omni (1993) 11:1936–1942.
   PubMed Web of Science ®Google Scholar
• HIRSCH FR, FRANKLIN WA, VEVE R, VARELLA-GARCIA M, BUNN PA JR: HER2/neu expression in malignant lung tumors. Semin. Oncol (2002) 29(1 Suppl. 4):51–58.
   PubMedGoogle Scholar
• PEGRAM MD, LOPEZ A, KONECNY G, SLAMON DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol (2000) 27(6 Suppl. 11):21–25.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HERZ for metastatic breast cancer that overexpresses HERZ. N Engl. J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• •First study demonstrating survival advantage combining chemotherapy with the mAb trastuzumab.
   Google Scholar
• LANGER C, ADAK S, THOR A et al.: Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer (NSCLC): early analysis of E2598.Proc. Am. Soc. Clin. Oncol (2001) 20:315a.
   Google Scholar
• KRUG L, MILLER V, CRAPANZANO J et al: Randomized Phase II trial of trastuzumab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Omni (2001) 20:333a.
   Web of Science ®Google Scholar
• ZINNER R, GLISSON B, PISTERS K et al.: Cisplatin and gemcitabine combined with herceptin in patients (pts) with HERZ overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC); a Phase II trial. Proc. Am. Soc. Clin. Oncol (2001) 20:328a.
   Google Scholar
• GATZEMEIER U, GROTH G, HIRSH V et al.: Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HERZ: results of a randomised Phase II study. Proc. Am. Soc. Clin. Oncol (2002) 21:297a.
   Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R et al Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053–2063.
   PubMed Web of Science ®Google Scholar
• FUKUOKA M, YANO S, GIACCONE G et al.: Final results from a Phase II trial of ZD 1839 (ressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol (2002) 21:298a.
   Web of Science ®Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al. A Phase II trial of ZD 1839 (ressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol (2002) 21:292a.
   Google Scholar
• GIACCONE G, JOHNSON DH, MANEGOLD C et al.: A Phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann. Oncol (2002) 13:2 (Abstract 40).
   Google Scholar
• •Study that failed to demonstrate any advantage by adding ZD 1839 to chemotherapy.
   Google Scholar
• JOHNSON DH, HERBST R, GIACCONE G et al: ZD 1839 (ressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a Phase III clinical trial (INTACT 2). Ann. Oncol (2002) 13:127 (Abstract 468o).
   Google Scholar
• •Study that failed to demonstrate any advantage by adding ZD 1839 to chemotherapy.
   Google Scholar
• CALVO B, CASKEY L, EARP H: Real-time fluorescent quantitative PCR reveals increased HERZ, HER3, and unchanged HER1 (EGFR) m RNA expression levels in colon carcinomas. Proceedings of the 2001 American Association for Cancer Research International Conference (2002) 7:3761s (Abstract 536).
   Google Scholar
• MOASSER MM, BASSO A, AVERBUCH SD, ROSEN N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. (2001) 61:7184–7188.
   PubMed Web of Science ®Google Scholar
• CAPPUZZO F, GREGORC V, BENEDETTI G et al.: ZD 1839 (IRESSA) in heavily pretreated locally advanced or metastatic non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HERZ and EGFR expression. Proceedings of the American Society of Clinical Oncology Molecular Therapeutics Symposium, San Diego, November 8–10 (2002):(Abstract 46).
   Google Scholar
• IWATA KK, PROVONCHA K, GIBSON N: Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc. Am. Soc. Clin. Oncol (2002) 21:21a.
   Google Scholar
• PEREZ-SOLER R, CHACHOUA A, HUBERMAN M et al.: A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Clin. Oncol (2001) 20:310a.
   Google Scholar
• FOROUZESH B, HIDALGO M, TAKIMOTO C et al.: Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc. Am. Soc. Clin. Oncol (2002) 21:21a.
   Google Scholar
• FORERO L, PATNAIK A, HAMMOND LA et al.: Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol (2002)21:256.
   Web of Science ®Google Scholar
• RINEHART JJ, WILDING G, WILLS ON J et al.: A Phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21:11a.
   Web of Science ®Google Scholar
• MITCHELL DY, REID JM, PARCHMENT RE et al.: Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral MEK inhibitor, CI-1040, following multiple dose administration to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:81a.
   Web of Science ®Google Scholar
• LORUSSO PM, ADJEI AA, MEYER MB et al.: A Phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:81a.
   Web of Science ®Google Scholar
• BOS JL: Ras oncogene in human cancer: a review. Cancer Res. (1989) 49:4682–4689.
   PubMed Web of Science ®Google Scholar
• RODENHUIS S, SLEBOS RJ, BOOT AJ et al: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. (1988) 48:5738–5741.
   PubMed Web of Science ®Google Scholar
• SLEBOS RJ, KIBBELAAR RE, DALESIO 0 et al.: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl. Med. (1990) 323:561–565.
   PubMed Web of Science ®Google Scholar
• KOHL NE, MOSSER SD, DESOLMS SJ et al.: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 260:1934–1937.
   PubMed Web of Science ®Google Scholar
• SEBTI SM, HAMILTON AD: Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene (2000) 19:6584–6593.
   PubMed Web of Science ®Google Scholar
• LIU M, BRYANT MS, CHEN J et al.: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. (1998) 58:4947–4956.
   PubMed Web of Science ®Google Scholar
• MOASSER MM, SEPP-LORENZINO L, KOHL NE et al.: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA (1998) 95:1369–1374.
   PubMed Web of Science ®Google Scholar
• KHURI F, GLISSON B, MEYERS M et al.: Phase I study of farnesyl transferase inhibitor (FTI) 5CH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc. Am. Soc. Clin. Oncol (2000) 19:205a.
   Web of Science ®Google Scholar
• ZUJEWSKI J, HORAK ID, BOL CJ et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol (2000) 18:927–941.
   PubMed Web of Science ®Google Scholar
• HUDES GR, SCHOL J, BAAB J et al: Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc. Am. Soc. Clin. Oncol (1999) 18:156a.
   Google Scholar
• PATNAIK A, IZBICKA E, ECKHARDT SC et al.: Inhibition of DHJ2 protein farnesylation in peripheral blood mononuclear cells as a pharmacodynamic endpoint in a Phase I study of R115777 and gemcitabine. Proc. Am. Assoc. Cancer Res. (2001) 42:488 (Abstract 2628).
   Google Scholar
• HOLDEN SN, ECKHARDT SC, FISHERS et al: A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (pts) with advanced solid malignancies. Proc. Am. Clin. Oncol. (2001) 20:80a.
   Google Scholar
• ADJEI AA, MAUER A, MARKS R et al.: A Phase II study of the farnesyltransferase inhibitor RU 5777 in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:290a.
   Google Scholar
• GOEKJIAN PG, JIROUSEK MR: Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Carr: Med. Chem. (1999) 6:877–903.
   PubMed Web of Science ®Google Scholar
• O'BRIAN C, VOGEL VG, SINGLETARY SE, WARD NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. (1989) 49:3215–3217.
   PubMed Web of Science ®Google Scholar
• DEAN N, MCKAY R, MIRAGLIA L et al.: Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. (1996) 56:3499–3507.
   PubMed Web of Science ®Google Scholar
• GEIGER T, MULLER M, DEAN NM, FABBRO D: Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. (1998) 13:35–45.
   PubMedGoogle Scholar
• YUEN AR, HALSEY J, FISHER GA et al.:Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. (1999) 5:3357–3363.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, HOLMLUND JT, KRAYNAK M et al.: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. Clin. Oncol. (1999) 17:3586–3595.
   Web of Science ®Google Scholar
• YUEN A, HALSEY J, FISHER G et al.: Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Am. Clin. Oncol. (2001) 20:309a.
   Google Scholar
• HERBST RS, THORNTON DE, KIES MS et al: Phase 1 study of LY317615, a protein kinase cl3 inhibitor. Proc. Am. Soc. Clin. Oncol. (2002) 21:82a.
   Google Scholar
• FONTANINI G, LUCCHI M, VIGNATI S et al.: Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. Natl. Cancer Inst. (1997) 89:881–886.
   Google Scholar
• FONTANINI G, VIGNATI S, BOLDRINI L et al.: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res. (1997) 3:861–865.
   PubMed Web of Science ®Google Scholar
• MACCHIARINI P, FONTANINI G, DULMET E et al: Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann. Thorac. Surg. (1994) 57:1534–1539.
   PubMed Web of Science ®Google Scholar
• VOLM M, MATTERN J, KOOMAGI R: Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. Int. Oncol. (1998) 13:975–979.
   PubMed Web of Science ®Google Scholar
• CURRAN S, MURRAY GI: Matrix metalloproteinases in tumour invasion and metastasis. Pathol. (1999) 189:300–308.
   Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. (2000) 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FR, GIACCONE G, DEBRUYNE C et al.: Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NCIC-CTG and EORTC study. Proc. Am. Clin. Oncol. (2001) 20:4a.
   Web of Science ®Google Scholar
• •Study that failed to demonstrate any survival advantage for marirnastat as maintenance therapy in SCLC.
   Google Scholar
• BONOMI P: Matrix metalloproteinases and matrix metalloproteinases inhibitors in lung cancer. Semin. Oncol. (2002) 29\(Suppl. 4):78–86.
   PubMedGoogle Scholar
• SMYLIE M, MERCIER R, ABOULAFIA D et al.: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc. Am. Clin. Oncol. (2001) 20:307a.
   Web of Science ®Google Scholar
• BISSETT D, O'BYRNE KJ, VON PAWEL J et al.: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung Cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:296a.
   Google Scholar
• GOLUB LM, LEE HM, RYAN ME, GIANNOBILE WV, PAYNE J, SORSA T: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. (1998) 12:12–26.
   PubMedGoogle Scholar
• RYAN ME, RAMAMURTHY S, GOLUB LM: Matrix metalloproteinases and their inhibition in periodontal treatment. Can: Opin. Periodontol (1996) 3:85–96.
   PubMedGoogle Scholar
• HERBST RS, HIDALGO M, PIERSON S et al.: Angiogenesis inhibitors in clinical development for lung cancer. Semin. Oncol. (2002) 29\(Suppl. 4):66–77.
   PubMedGoogle Scholar
• FERRARA N: Molecular and biological properties of vascular endothelial growth factor. Mol. Med. (1999) 77:527–543.
   Web of Science ®Google Scholar
• KUKK E, LYMBOUSSAKI A, TAIRA S et al.: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 122:3829–3837.
   PubMed Web of Science ®Google Scholar
• DE VORE R, FEHRENBACHER L, HERBST R et al.: A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Clin. Oncol. (2000) 19:485a.
   Google Scholar
• JOHNSON D, DEVORE R, KABBINAVAR F et al.: Carboplatin (C) + paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Clin. Oncol. (2001) 20:315a.
   Google Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of 5U5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. (2000) 15:29–41.
   PubMedGoogle Scholar
• FONG TA, SHAWVER LK, SUN L et al.:5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• ELLIS LM, TAKAHASHI Y, LIU W, SHAHEEN RIVI: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist (2000) 5:11–15.
   PubMedGoogle Scholar
• SHAHEEN PM, DAVIS DW, LIU W et al.: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
   PubMed Web of Science ®Google Scholar
• ROSEN L, MULAY M, MAYERS A et al.: Phase 1 dose-escalating trial of 5U5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (1999) 18:161a.
   Google Scholar
• CROPP G, ROSEN L, MULAY M et al.: Pharmacokinetics and pharmacodynamics of 5U5416 in a Phase I, dose escalating trial in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (1999) 18:161a.
   Google Scholar
• STOPECK A: Results of a Phase I dose-escalating study of the antiangiogenic agent, 5U5416, in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2000) 19:206a.
   Google Scholar
• KUENEN BC, ROSEN L, SMIT EF et al: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and 5U5416 in patients with solid tumors. j. Clin. Oncol (2002) 20:1657–1667.
   PubMed Web of Science ®Google Scholar
• HOEKMAN K, KUENEN B, LEVI M et al.: Activation of the coagulation cascade and endothelial cell perturbation during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor 5U5416.Proc. Am. Soc. Gin. Oncol (2002) 21:6a.
   Google Scholar
• ROSEN L, ROSEN P, KABBINAVAR F et al.: Phase I Experience with 5U6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc. Am. an. Oncol (2001) 20:97a.
   Web of Science ®Google Scholar
• SUGARBAKER E, THORNWAITE J, KETCHAM A: Inhibitory effect of a primary tumor on metastasis. In: Progress in Cancer Research and Therapy Day S, Meyer P, Stansly P et al. (Eds), Raven Press, NY, USA (1977):227–240.
   Google Scholar
• ITO H, ROVIRA II, BLOOM M et al: Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. (1999) 59:5875–5877.
   PubMed Web of Science ®Google Scholar
• DEMORAES E, FOGLER W, GRANT D et al.: Recombinant human angiostatin (rhA): a Phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc. Am. an. Oncol (2001) 20:3a.
   Google Scholar
• VOEST EE, BEEREPOOT LV, GROENEWEGEN G et al.: Phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:81a.
   Web of Science ®Google Scholar
• EDER JP JR, SUPKO JG, CLARK JW et al.: Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. Oncol (2002) 20:3772–3784.
   Google Scholar
• HERBST RS, HESS KR, TRAN HT et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. .1 Clin. Oncol. (2002) 20:3792–3803.
   Google Scholar
• HERBST RS, MULLANI NA, DAVIS DW et al.: Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. an. Oncol (2002) 20:3804–3814.
   Google Scholar
• MOORE KS, WEHRLI S, RODER H et al.: Squalamine: an aminosterol antibiotic from the shark. Proc. Natl. Acad. Sci. USA (1993) 90:1354–1358.
   PubMed Web of Science ®Google Scholar
• SILLS AK JR, WILLIAMS JI, TYLER BM et al.: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res. (1998) 58:2784–2792.
   PubMed Web of Science ®Google Scholar
• KALIDAS M, HAMMOND LA, PATNAIK A et al.: A Phase I and pharmacokinetic (PK) study of the angiogenesis inhibitor, squalamine lactate (MSI-1256F). Proc. Am. Soc. an. Oncol. (2000) 19:180a.
   Google Scholar
• CASIBANG M, PURDOM S, JAKOWLEW S et al: Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer (2001) 31:203–212.
   PubMed Web of Science ®Google Scholar
• LIU CH, CHANG SH, NARKO K et al: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. (2001) 276:18563–18569.
   PubMed Web of Science ®Google Scholar
• ACHIWA H, YATABE Y, HIDA T et al.: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Cilia. Cancer Res. (1999) 5:1001–1005.
   PubMed Web of Science ®Google Scholar
• KHURI FR, WU H, LEE JJ et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Gin. Cancer Res. (2001) 7:861–867.
   Web of Science ®Google Scholar
• SORIANO AF, HELFRICH B, CHAN DC, HEASLEY LE, BUNN PA JR, CHOU TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. (1999) 59:6178–6184.
   PubMed Web of Science ®Google Scholar
• HIDA T, KOZAKI K, MURAMATSU H et al.: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. an. Cancer Res. (2000) 6:2006–2011.
   Web of Science ®Google Scholar
• CSIKI I, DANGT, GONZALEZ A et al: Cyclooxygenase-2 (COX-2) inhibition + docetaxel (TXT) in recurrent non-small cell lung cancer (NSCLC): preliminary results of a Phase II trial (TH0-0054). Proc. Am. Soc. an. Oncol (2002) 21:297a.
   Web of Science ®Google Scholar
• ALTORKI NK, KERESZTES RS, PORT JL et al.: Celecoxib (celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/ carboplatin in early stage non-small cell lung cancer. Proc. Am. Soc. Gin. Oncol (2002) 21:26a.
   Google Scholar
• ROTH JA, NGUYEN D, LAWRENCE DD et al.: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. (1996) 2:985–991.
   PubMed Web of Science ®Google Scholar
• SWISHER SG, ROTH JA, NEMUNAITIS J et al: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1999) 91:763–771.
   PubMed Web of Science ®Google Scholar
• SWISHER SG, ROTH JA, CARBONE DP: Genetic and immunologic therapies for lung cancer. &min. Oncol. (2002) 29(1 Suppl. 4):95–101.
   Google Scholar
• NGUYEN DM, SPITZ FR, YEN N, CRISTIANO RJ, ROTH JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thome. Cardiovasc. Surg. (1996) 112:1372–1376.
   PubMed Web of Science ®Google Scholar
• SPITZ FR, NGUYEN D, SKIBBER JM, MEYN RE, CRISTIANO RJ, ROTH JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells
   Google Scholar